Delayed
OTC Markets
01:31:15 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
1.08
USD
|
-1.82%
|
|
-1.82%
|
+77.78%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
0.202
|
0.5098
|
0.3059
|
0.5773
|
0.6298
|
3.189
|
Enterprise Value (EV)
1 |
1.577
|
0.5078
|
0.3309
|
0.6322
|
0.7057
|
3.285
|
P/E ratio
|
-1.13
x
|
0.92
x
|
-1.64
x
|
-3.89
x
|
-4.34
x
|
-21.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
6,436,929
x
|
24,504,671
x
|
21,149,485
x
|
96,845,975
x
|
FCF Yield
|
-
|
-
|
0%
|
0%
|
0%
|
0%
|
Price to Book
|
-0.06
x
|
-149
x
|
-2.48
x
|
-1.92
x
|
-1.41
x
|
-5.39
x
|
Nbr of stocks (in thousands)
|
2,448
|
4,248
|
4,248
|
5,249
|
5,249
|
5,249
|
Reference price
2 |
0.0825
|
0.1200
|
0.0720
|
0.1100
|
0.1200
|
0.6075
|
Announcement Date
|
4/2/19
|
4/9/20
|
4/14/21
|
3/4/22
|
1/31/23
|
4/5/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.1426
|
-0.1516
|
-0.208
|
-0.1457
|
-0.141
|
-0.1409
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-0.1783
|
0.4266
|
-0.209
|
-0.1484
|
-0.1451
|
-0.1462
|
Net income
1 |
-0.1783
|
0.4266
|
-0.209
|
-0.1484
|
-0.1451
|
-0.1462
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0728
|
0.1305
|
-0.0438
|
-0.0283
|
-0.0276
|
-0.0279
|
Free Cash Flow
|
-
|
-
|
0.0514
|
0.0258
|
0.0334
|
0.0339
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/2/19
|
4/9/20
|
4/14/21
|
3/4/22
|
1/31/23
|
4/5/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1.38
|
-
|
0.03
|
0.05
|
0.08
|
0.1
|
Net Cash position
1 |
-
|
0
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
0.05
|
0.03
|
0.03
|
0.03
|
ROE (net income / shareholders' equity)
|
5.43%
|
-25.3%
|
268%
|
65.5%
|
38.9%
|
28.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-9,945%
|
-20,605%
|
-42,583%
|
-10,264%
|
Assets
1 |
-
|
-
|
0.002101
|
0.00072
|
0.000341
|
0.001424
|
Book Value Per Share
2 |
-1.380
|
-0
|
-0.0300
|
-0.0600
|
-0.0800
|
-0.1100
|
Cash Flow per Share
|
-
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/2/19
|
4/9/20
|
4/14/21
|
3/4/22
|
1/31/23
|
4/5/24
|
|
1st Jan change
|
Capi.
|
---|
| +77.78% | 44.89M | | +51.57% | 63.85B | | -2.38% | 41.83B | | +40.01% | 40.47B | | -10.22% | 27.17B | | +13.73% | 26.52B | | -21.42% | 18.69B | | +2.92% | 12.73B | | +22.45% | 12.11B | | +27.93% | 12.07B |
Other Biotechnology & Medical Research
|